Corrigendum to “Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18–60 years: A double-blind, non-inferiority, randomized controlled trial” [Vaccine 42(9) (2024) 2254–2259]

2026-06-28

PRE

Amirreza Keyvanfar

Hossein Keyvani *

Shahnaz Sali

DOI：10.1016/j.vaccine.2026.128881

Original request for help

Save

Abstract

IF:

3.5

Papers:

2.1K

Citations:

4.7W

Scholars:

1.5K

Papers: 665

Citations: 0

Scholars:

1.7K

Papers: 751

Citations: 1.1W